https://adisinsight.springer.com/trials/700364089?error=cookies_not_supported&code=3d508c6e-3d2c-4850-b765-3674935c3055
A Multicenter, Phase 3 Clinical Trial of Gemcitabine and Camrelizumab Plus Apatinib Versus...
This study aims to explore a new, more effective and tolerable treatment regimen for patients with advanced recurrent/metastatic nasopharyngeal carcinoma.
https://adisinsight.springer.com/trials/700392295?error=cookies_not_supported&code=c72776a7-b708-41aa-a62e-9a6d16d232dd
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy...
In pMMR/MSS locally advanced rectal cancer, can the innovative "chemo-immunotherapy induction + LCRT + chemo-immunotherapy consolidation" approach
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1502701/full
Frontiers | Analysis of the efficacy and safety of camrelizumab combined with chemotherapy for...
IntroductionIn this study, we explored the effectiveness and safety of the immune checkpoint inhibitor camrelizumab in combination with chemotherapy for the ...
efficacy and safetyof the
https://adisinsight.springer.com/trials/700386324?error=cookies_not_supported&code=8c58804c-2d7b-48ef-b019-b27c41f624c5
Exploratory Clinical Study of Camrelizumab Combined With Pirfenidone and Chemotherapy in the...
This is a prospective, single-arm, exploratory clinical study, planned to enroll 12 patients with advanced triple-negative breast cancer who have received
clinical study
https://adisinsight.springer.com/drugsafety/803861815?error=cookies_not_supported&code=f22d13b3-2b44-4197-bb2e-83a04a5c1b09
Camrelizumab/catequentinib - AdisInsight
In a retrospective study of 68 patients with metastatic colorectal cancer (CRC), who enrolled between August 2018 and December 2022, a woman [age not stated]
adisinsight
https://adisinsight.springer.com/trials/700379960?error=cookies_not_supported&code=876807c6-44f7-459c-9947-33f4b6221e4f
Camrelizumab and Rivoceranib Plus HAIC As Conversion Therapy for Potentially Resectable...
The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion
conversion therapyplushaic
https://adisinsight.springer.com/drugsafety/803668012?error=cookies_not_supported&code=868dc626-790e-4eb5-92dc-b6d19af19c8b
Camrelizumab/rivoceranib - AdisInsight
In a single-center retrospective study of 108 patients, treated during March 2017 to May 2021, two patients [ages and sexes not stated] were described, who
adisinsight
https://adisinsight.springer.com/drugsafety/803926354?error=cookies_not_supported&code=2b82761f-e31a-44a1-8ce3-e004aefc32be
Camrelizumab/Gemcitabine/Paclitaxel - AdisInsight
Seventeen patients with pancreatic ductal adenocarcinoma and liver metastases received camrelizumab, gemcitabine and paclitaxel and experienced adverse drug
gemcitabinepaclitaxeladisinsight
https://adisinsight.springer.com/trials/700392189?error=cookies_not_supported&code=b48441c3-957c-4114-85eb-9d9be9ee2178
Short-Course Radiotherapy Followed by Liposomal Irinotecan, Capecitabine, and Camrelizumab as...
This study is for adults with locally advanced rectal cancer that has not spread to distant organs, and is classified as pMMR or MSS (which means it typically
short coursefollowed byradiotherapy
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.735536/full
Frontiers | Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as...
Objective: The CAMEL clinical trial (412 patients were randomly assigned to either camrelizumab plus chemotherapy (n=205) or chemotherapy alone (n=207)) demo...
cost effectivenessfrontiersanalysis